Table 1. Baseline characteristics of study subjects.
| Baseline Parameters | Values |
|---|---|
| Male gender, N (%) | 244 (70.9) |
| Age (year) | 56.8 ± 11.8 |
| DM duration (year) | 6.5 ± 7.6 |
| O3FAs dosage | 1875.0 ± 796.5 |
| 1 g/day, N (%) | 103 (29.9) |
| 2 g/day, N (%) | 211 (61.3) |
| 4 g/day, N (%) | 30 (8.7) |
| BMI (kg/m2) | 26.0 ± 3.4 |
| Smoking, N (%) | 152 (44.2) |
| Drinking alcohol, N (%) | 147 (42.7) |
| Hypertension, N (%) | 256 (74.4) |
| Systolic blood pressure (mmHg) | 127.8 ± 15.1 |
| Diastolic blood pressure (mmHg) | 74.9 ± 9.6 |
| Medications, N (%) | |
| ACEi/ARB | 247 (71.8) |
| CCB | 151 (43.9) |
| SU | 154 (44.8) |
| Metformin | 268 (77.9) |
| DPP4i | 126 (36.6) |
| TZD | 46 (13.4) |
| Insulin | 59 (17.2) |
| Fenofibrate | 54 (15.7) |
| Statin | 211 (61.3) |
| Ezetimibe | 42 (12.2) |
Data are presented as N (%) or mean ± SD. DM, diabetes mellitus; O3FAs, omega-3 fatty acids; BMI, body mass index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione.